RxDoctor Payments Data

Donald Gauldin, MD

Ophthalmology · Little Rock, ARNPI 1871912204

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 55 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 28.2% of the total. Reporting peaked in 2023 at $353 and has fallen 69.3% since, to $109 in 2025.

$1,218in general payments, 2019–2025

Across 55 payments — averaging $22.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$343
  • Alcon$160
  • Biotissue Holdings Inc.$129
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$126
  • Bausch & Lomb Americas Inc.$69
  • Novartis$66
  • plus $325 from 11 others

What the payments were for

  • Food & beverage$1,218100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,218 in reported general payments places this provider in the 60th percentile of 125 ophthalmology providers in Arkansas.

See all ophthalmology providers in Arkansas

Medicare billing

Part B allowed, 2024
$435,375
Medicare patients
858
Services billed
3,646

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost157$60,336
CombiganBrimonidine Tartrate/Timolol74$21,749
Alphagan PBrimonidine Tartrate17$10,386
Latanoprost1,059$8,146
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat551$7,008
RocklatanNetarsudil Mesylat/Latanoprost12$4,227
Brimonidine Tartrate162$4,183
Travoprost42$3,658
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol42$3,562
Prednisolone Acetate97$3,323
MoxifloxacinMoxifloxacin Hcl58$1,966
Ketorolac Tromethamine54$1,558
Timolol Maleate144$1,400
ErythromycinErythromycin Base86$932
Dorzolamide Hcl58$753

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Alphagan P$343$92,470248 claims
Aerie Pharmaceuticals, Inc.Rocklatan$23$4,22712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 125 ophthalmology providers in Arkansas.

Other ophthalmology in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →